Eli Lilly
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …
Eli Lilly’s Zepbound approved by FDA for chronic weight management
November 9, 2023Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight …
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
October 27, 2023Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …
Eli Lilly to acquire POINT Biopharma
October 4, 2023Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
September 25, 2023Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …
Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo
August 23, 2023Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …
Eli Lilly shares data from two phase 3 tirzepatide studies
July 28, 2023Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss
Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …
Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment
July 18, 2023Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab
Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …
Eli Lilly to acquire Versanis Bio for $1.9bn
July 17, 2023Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases
Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …
Eli Lilly to acquire Sigilon Therapeutics
June 30, 2023Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition
Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …
Eli Lilly to acquire DICE Therapeutics for immunology innovations
June 21, 2023Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology
Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …
Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease
May 5, 2023Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug
Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …
Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis
May 3, 2023Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab
Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …
Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials
June 28, 2021Sales and Marketing Eli Lilly, semaglutide, type 2 diabetes
Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C and body weight reductions compared …
Eli Lilly to seek FDA approval for experimental Alzheimer’s drug
June 25, 2021Medical Communications Alzheimer's, Eli Lilly, FDA
Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
